Under the terms of the five-year contract, Cangene could be awarded delivery orders for the collection and storage of anti-Anthrax human plasma, for the manufacturing of bulk drug substance and AIGIV final drug product. The contract's work statement has a total potential maximum value of approximately $264 million to Cangene.
In conjunction with the contract award, Cangene was awarded the first task/delivery order under the contract. The order is for the collection and storage of anti-Anthrax human plasma sufficient to manufacture 10,000 doses of bulk drug substance or final drug product. This order is expected to generate aggregate revenue of approximately $63 million for Cangene for fiscal years 2014, 2015 and 2016 and is included in the $264 million potential value estimate.
John A. Sedor, president and chief executive officer of Cangene, commented, "We are proud to have been selected by the U.S. government for this important medical countermeasure. This marks our second major biodefense contract this year, with the extension of our VIGIV contract with the Centers for Disease Control and Prevention that we announced earlier this month, underscoring our leadership in biodefense. We appreciate our long-standing relationship with the U.S. Department of Health and Human Services, and look forward to continuing to support its critical biodefense preparedness program."
This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201300009I.